MODERNA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 154.7 USD | -0.10% |
|
+2.11% | +55.55% |
| 08:50pm | S&P 500, Nasdaq dip on the eve of US payrolls data | RE |
| 06:46pm | Wall Street mixed as Nvidia retreat hits tech stocks; payrolls data in focus | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
154.8
USD
Average target price
142.8
USD
Spread / Average Target
-7.77%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +55.55% | 59.34B | |
| +43.17% | 40.24B | |
| -4.71% | 39.88B | |
| -5.56% | 28.55B | |
| +13.76% | 27.26B | |
| -22.00% | 19.23B | |
| +31.50% | 12.61B | |
| +2.16% | 12.49B | |
| +25.70% | 12.28B | |
| -6.25% | 11.13B |
- Stock Market
- Equities
- MRNA Stock
- News Moderna, Inc.
- Moderna Suffers Setback in Lawsuit by Arbutus
